Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.395 USD | +7.72% | +0.95% | +13.90% |
May. 10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
May. 10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.90% | 464M | |
+4.88% | 109B | |
+11.63% | 105B | |
+0.55% | 22.25B | |
-11.56% | 22.09B | |
-7.89% | 18.68B | |
-38.36% | 17.58B | |
-9.26% | 16.85B | |
+4.36% | 13.76B | |
+36.96% | 12.46B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Transcript : Fate Therapeutics, Inc., Q3 2021 Earnings Call, Nov 04, 2021